Held by 3 specialist biotech funds
High Convergence# Signal Note: OrbiMed Initiates $27M Position in Janux Therapeutics OrbiMed's entry into JANX signals confidence in the company's dual-specificity antibody platform, likely driven by upcoming clinical catalysts in its lead program—a TIGIT/PD-1 bispecific for solid tumors expected to advance through Phase 2 readouts in 2024-2025.
AI analyst context — unlock full analysis
# Signal Note: RA Capital Initiates $154M Position in JANX RA Capital's $154M entry into Janux signals confidence in the company's bispecific platform, particularly JTX-4014 (CD4/CD25 bispecific) for autoimmune diseases where it has demonstrated clinical differentiation versus monotherapy approaches. The position sizing suggests conviction around near-term catalysts, likely including upcoming Phase 2 data readouts in lupus nephritis and other autoimmune indications expected through 2024-2025. Given Kolchinsky's track record of early-stage conviction plays, this indicates institutional-grade validation of Janux's mechanism and clinical trajectory before broader market recognition.
+ 1 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial